Download PDFPDF

TP011/#1536  A double-blind placebo-controlled phase III chemo-immunotherapy (Paclitaxel-carboplatin-oregovomab [PCO]) vs chemotherapy (Paclitaxel-carboplatin-placebo [PCP]) in patients with newly diagnosed, advanced epithelial ovarian cancer (EOC): FLORA-5/GOG-3035 study
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address